Morgan Stanley upgrades Nexa Resources stock rating on zinc price outlook

Morgan Stanley upgraded Nexa Resources to Overweight from Equalweight and raised its price target to $14.20 from $13.50, implying about 14% upside. The firm said higher zinc forecasts lift its 2027–2028 EBITDA estimates by 20%–28% and EPS estimates by 51%–53%; a potential Boliden buyout premium could imply $16.50–$19.80 per share. Nexa’s Q2 2026 revenue beat expectations at $907.9 million versus $880.5 million, while EPS missed at $0.52 versus $0.77; Boliden has agreed to acquire Votorantim’s 64.68% stake in an all-share deal valuing Nexa at $15.29 per share.

Analysis

NEXA offers two distinct exposures that should not be conflated: leveraged sensitivity to zinc/copper and a deal spread tied to Boliden’s proposed transaction. The commodity case is a forecast, not a realized earnings inflection; the recent EPS miss despite revenue above expectations is a reminder that costs, production, financing, taxes or other items can absorb higher prices. Verify the miss drivers and mine-level output/cost guidance before underwriting the cited EBITDA sensitivity. If price strength persists, operating leverage could make estimates move faster than the stock, but that is a 1–3 quarter, not immediate, catalyst.

The event-driven case may be more near-term, but the reported ~6% discount to offer terms is not automatically mispricing: confirm the exact consideration, exchange-ratio mechanics, conditions, timetable, and treatment of minority holders. Boliden’s capacity to pay more is Morgan Stanley’s assessment, not evidence it will revise terms. A higher bid could benefit NEXA holders while raising the acquisition cost and execution burden for Boliden; an all-share structure also leaves consideration exposed to BOL’s share price.

Contrarian read: low valuation and analyst upside cases can overstate equity optionality if the EPS shortfall reflects persistent operational or cost problems. The apparent discount and commodity upside may already be partly anticipated; avoid paying for both as certain. Key reversals are weaker zinc/copper, disappointing cost or production disclosures, a delayed/changed transaction, or a decline in BOL that reduces offer value.

Key Decisions for Investors

• Treat NEXA as a watchlist/event-driven long, not a valuation-only buy. First reconcile the Q2 EPS miss to segment-level costs, volumes, financing and taxes, and verify current offer documentation; reassess if those checks support both earnings delivery and the stated consideration.
• For a 1–3 month catalyst, monitor deal approvals, tender terms and closing timetable. Consider a modest NEXA position only if the discount remains after adjusting for BOL share-price exposure and deal conditions; do not assume a higher premium. Exit or cut risk if terms worsen, the process materially slips, or BOL weakness erodes the implied value.
• For a 6–18 month commodity thesis, add NEXA exposure only alongside confirmation in realized zinc/copper prices and company production/cost guidance. Falsify the thesis on sustained commodity-price reversal or further operational/earnings misses; avoid sizing from the broker’s forecast sensitivity alone.
• No direct STZ or MS trade follows from this item. Keep BOL on the event-risk monitor: a richer bid may improve strategic control but increases consideration and integration risk, while a lower BOL share price can reduce the value of an all-share offer.